Literature DB >> 17473214

Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors.

Alastair H Kyle1, Lynsey A Huxham, Devon M Yeoman, Andrew I Minchinton.   

Abstract

PURPOSE: Limited drug penetration in solid tumors is a potential mechanism of resistance for many anticancer drugs. Taxanes represent a class of drugs that are currently undergoing a new round of development, but with little known of their ability to penetrate and distribute relative to blood vessels within solid tumors. EXPERIMENTAL
DESIGN: We assessed the tissue penetration of paclitaxel and docetaxel in HCT-116 tumor xenografts and in multilayered cell culture (MCC), a three-dimensional cell culture model of the tumor extravascular compartment. In xenografts, taxanes were mapped relative to blood vessels to obtain drug profiles as a function of distance from vasculature. For MCC, cultures were exposed to stirred drug reservoirs and taxanes measured as a function of depth into tissue.
RESULTS: Both taxanes exhibited limited penetration, with little drug reaching further than 100 microm into the tissue. Of the two, paclitaxel exhibited up to 2-fold greater penetration than docetaxel. Mapping tumor cell proliferation following treatment allowed the consequences of limited drug penetration to be assessed. In tumor xenografts where reduced drug exposure to cells far from vasculature is one of several factors influencing response to treatment, up to a 75% reduction in S-phase cells was achieved in cells nearest the vessels, but only 50% reduction was observed in the tissue 150 microm away. In MCC-based data, where the influence of reduced cell proliferation with depth into tissue was circumvented, a 5-fold (paclitaxel) and 10-fold (docetaxel) increase in reservoir drug concentration was required to produce a response in cells 150 microm into the tissue equivalent to that seen in cells directly exposed to the drug.
CONCLUSION: These results indicate that limited distribution is an important mechanism of tumor resistance to taxanes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17473214     DOI: 10.1158/1078-0432.CCR-06-1941

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  60 in total

1.  Intra-tumoral drug concentration mapping within solid tumor micro-milieu using in-vitro model and doxorubicin as a model drug.

Authors:  Ahmed M Al-Abd; Alaa Khedr; Salah G Atteiah; Fahad A Al-Abbasi
Journal:  Saudi Pharm J       Date:  2020-05-11       Impact factor: 4.330

2.  Development and optimization of near-IR contrast agents for immune cell tracking.

Authors:  Pratixa P Joshi; Soon Joon Yoon; Yun-Sheng Chen; Stanislav Emelianov; Konstantin V Sokolov
Journal:  Biomed Opt Express       Date:  2013-10-24       Impact factor: 3.732

Review 3.  Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities.

Authors:  Carolyn L Waite; Charles M Roth
Journal:  Crit Rev Biomed Eng       Date:  2012

4.  A model based analysis of IPEC dosing of paclitaxel in rats.

Authors:  Pieter Colin; Lieselotte De Smet; Chris Vervaet; Jean-Paul Remon; Wim Ceelen; Jan Van Bocxlaer; Koen Boussery; An Vermeulen
Journal:  Pharm Res       Date:  2014-05-22       Impact factor: 4.200

Review 5.  Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.

Authors:  E S Antonarakis; A J Armstrong
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-05-17       Impact factor: 5.554

6.  High-Content Screening Comparison of Cancer Drug Accumulation and Distribution in Two-Dimensional and Three-Dimensional Culture Models of Head and Neck Cancer.

Authors:  Feng Shan; David A Close; Daniel P Camarco; Paul A Johnston
Journal:  Assay Drug Dev Technol       Date:  2017-12-07       Impact factor: 1.738

7.  Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitors.

Authors:  Greg M Thurber; Thomas Reiner; Katherine S Yang; Rainer H Kohler; Ralph Weissleder
Journal:  Mol Cancer Ther       Date:  2014-02-19       Impact factor: 6.261

8.  Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo.

Authors:  Greg M Thurber; Katy S Yang; Thomas Reiner; Rainer H Kohler; Peter Sorger; Tim Mitchison; Ralph Weissleder
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 9.  Treatment strategies for gastric cancer patients with peritoneal metastasis.

Authors:  Motohiro Imano; Kiyotaka Okuno
Journal:  Surg Today       Date:  2013-05-16       Impact factor: 2.549

10.  The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors.

Authors:  Krupa J Patel; Ian F Tannock
Journal:  BMC Cancer       Date:  2009-10-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.